Cost Effectiveness of Tofacitinib as Second Line Treatment vs Using Biological Therapies In The Treatment of Moderate Rheumatoid arthritis after Failure of dmards In Panama In 2014
May 1, 2015, 00:00
10.1016/j.jval.2015.03.939
https://www.valueinhealthjournal.com/article/S1098-3015(15)00996-1/fulltext
Title :
Cost Effectiveness of Tofacitinib as Second Line Treatment vs Using Biological Therapies In The Treatment of Moderate Rheumatoid arthritis after Failure of dmards In Panama In 2014
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00996-1&doi=10.1016/j.jval.2015.03.939
First page :
A162
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
388